NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Mechanism of Action
2 diabetes mellitus: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide class. Alogliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the…
Indications (2)
Clinical Trials (2)
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Started Feb 2017
1,026 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Started Jan 2007
480 enrolled
Diabetes Mellitus, Type 2
Loss of Exclusivity
LOE Date
May 24, 2029
39 months away
Patent Expiry
May 24, 2029
Exclusivity Expiry
Jul 27, 2026